2015考研英语阅读癌症治疗_大学英语阅读

2015考研英语阅读癌症治疗

　　虽然人数不是很多，但这些病人的反应很强烈。有些人可以存活几年而没有疾病特征。

　　Ipilimumab s successors have pushed the response rate up while maintaining the long-termbenefits.

　　易普利姆玛的后续制剂提高了反应比例，同时维持长期效果。

　　A trial of nivolumab, led by Mario Sznol of the Yale Cancer Centre, showed a success rate ofalmost a third in a group of 107 melanoma patients, when success was defined as a tumourshrinking by 30% or more.

　　耶鲁大学癌症中心Mario Sznol 对Nivolumab进行了试验，按照肿瘤缩小至少30%的标准，参与该试验的107名黑色素瘤病人中有三分之一取得了良好的治疗效果，

　　The median survival time of these successes has so far been 16.8 months, quite a gain overthe nine months that might have been expected for such people just a few years ago.

　　目前存活时间的中位数为16.8个月，这要比前些年对这类病人存活期的预期增加了9个月，已经算相当长了。

　　Lambrolizumab, too, looks promising.

　　Lambrolizumab也很有前景。

　　Antoni Ribas of the University of California, Los Angeles, and his colleagues reported to themeeting that the tumours of more than a third of the 135 advanced-melanoma patientswhom they had treated with it have shrunk.